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Abstract We here report that the M, 40,000 receptor associated protein (RAP), previously found to bind to a,-macroglobulin receptor/low density 
lipoprotein receptor related protein (a,MR/LRP) and glycoprotein 330 (gp330), binds to an M, 105,000 membrane protein from bovine mammary 
gland, human mamma tumors and mammary epithelial cell lines. We have purified this protein from bovine and human sources. N-terminal amino 
acid sequencing and immunoblotting analyses showed that the protein was identical or closely related to very low density lipoprotein receptor 
(VLDL-R). Experiments with the human mamma carcinoma cell line MCF-7 showed that this receptor was able to mediate an efficient endocytosis 
of RAP. These novel findings strongly suggest that RAP functions as a modulator of ligand binding to VLDL-R, similarly to a,MR/LRP and 
gp330. 
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1. Introduction 
The low density lipoprotein receptor (LDL-R) family of cell 
membrane receptors currently includes LDL-R itself, a,-mac- 
roglobulin receptor/low density lipoprotein receptor related 
protein (a,MR./LRP), glycoprotein 330 (gp330), and very low 
density lipoprotein receptor (VLDL-R). They are endocytosis 
receptors and participate in clearance of lipoproteins, pro- 
teinaselinhibitor complexes and a variety of other compounds 
from the extracellular space and cell surfaces. LDL-R and 
VLDL-R have M,s between 100,000 and 200,000, while a,MRI 
LRP and gp330 have M,s around 600,000. All have a small, 
C-terminal cytoplasmic domain, a single trans-membrane do- 
main, and a large, ligand-binding extracellular part. 
Alpha,MR/LRP differs from the others by being split into two 
non-covalently linked polypeptide chains, encoded by a single 
mRNA: an 1%4, 515,000 a-chain, containing most of the ex- 
tracellular portion and being responsible for ligand binding, 
and an A4,85,000j?-chain, spanning a small part of the extracel- 
lular domain, the trans-membrane domain and the cytoplasmic 
portion (for reviews see [1,2]). 
During purification of a,MWLRP, a copurifying M, 40,000 
receptor associated protein (RAP) was discovered [3,4]. A 
cDNA representing human RAP was cloned by Strickland 
et al. [5]. RAP is now known to bind with high affinity to 
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a,MRILRP and gp330. Two or more RAP molecules are bound 
per receptor molecule (see [2]). A low affinity binding to LDL-R 
has been reported [6]. RAP inhibits the binding of all other 
currently known ligands to cqMR/LRP and gp330, but its phys- 
iological function remains to be established (see [2]). 
In the present communication, we describe that RAP binds 
to VLDL-R from mammary tissue and cell lines, and that 
VLDL-R is able to mediate endocytosis of RAP in a cell line 
derived from mammary epithelium. 
2. Materials and methods 
2.1. Proteins, antibodies and various materials 
Recombinant human RAP was prepared as described earlier [7l. 
Human a*-macroglobulin-methyl amine (a2M*) [8] was a gift from 
Dr. L. Sottrup-Jensen, Department of Molecular Biology, University 
of Aarhus, Denmark. Alpha,MR/LRP [7] was a gift from Drs. A. 
Nykjrer and J. Gliemann, Department of Medical Biochemistry, Uni- 
versity of Aarhus, Denmark. 
Labelling of proteins with ‘*‘I was done as described [7,9]. The spe.- 
cific activities were around 2.5 x IO6 Ciimol. 
A rabbit polyclonal antibody, raised against a synthetic peptide 
ASVGHTYPAISWSTDDDLA, which represents the C-terminus of 
rabbit and human VLDL-R [lO,ll], was a gift from Drs. M.Z. Kounnas 
and D.K. Strickland, American Red Cross, Washington, USA. 
Human tumor specimens were obtained from Dr. L. Christensen, 
Rigshospitalet, Copenhagen, Denmark. 
ProBlott membranes and reagents used for protein sequencing were 
purchased from Applied Biosystems (Foster City, CA, USA). The ECL 
immunoblotting detection kit was from Amersham, Little Chalfont, 
UK. All other chemicals and materials were those previously described 
[7,9,12-141, or of the best grade commercially available. 
2.2. Preparation of cell membranes 
Large scale-preparation of cell membranes from bovine mammary 
gland was performed with tissue obtained from newly slaughtered cows 
at the local slaughterhouse. All procedures were performed at 04°C. 
Approximately 0.5 kg of tissue was rinsed with phosphate-buffered 
saline (PBS; 10 mM NaH,PO,, 0.15 M NaCl), finely minced and then 
homogenized by the use of an Ultra-Turrax (25,000 rpm, 3 min) in a 
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buffer of 10 mM HEPES, pH 7.4, 250 mM sucrose, 5 mM EDTA and 
0.5 mM phenyl-methyl-sulfonyl flouride (PMSF), using 2 ml buffer per 
1 g wet weight of tissue. Cell debris and nuclei were sedimented by 
centrifugation at 2,300 x g for 5 min. Membrane fragments were precip- 
itated by centrifugation at 48,000 x g for 40 min. The pellet was reho- 
mogenized in 200 ml of a buffer of 10 mM NaH,PO,, pH 7.8,140 mM 
NaCl, 0.6 mM CaCl, and 0.5 mM PMSF, and centrifuged as above. 
The pellet represented the membrane preparation. 
Small-scale preparation of cell membranes from cultured cells and 
samples of human tissues were performed similarly, but using 10 ml 
buffer per 1 g wet weight of cells and tissues during homogenization. 
2.3. Purification of RAP-binding proteins from cell membranes 
Cell membranes were solubilized by homogenization in l-2 1 of the 
following buffer: 20 mM HEPES, 2.5 mM NaH,PO,, pH 7.4, 124 mM 
NaCl, 4.7 mM KCl, 2.5 mM CaCl,, 1.2 mM MgSO, and 0.5 mM 
PMSF, with 0.6% 3-[(3-cholamidopropyl)dimethyl-ammonio]-l- 
propanesulfonate (CHAPS). The solution was centrifuged at 10,000 x g 
and passed through a 1.2 pm filter to remove insoluble material. 
Cell membrane xtract was applied to a 4 ml column of Sepharose 
4B coupled with approximately 10 mg RAP. The column was equili- 
brated in the buffer also used for solubilizing the membranes. The 
column was washed with 0.1 M Tris, pH 7.8, 0.14 M NaCl, 2 mM 
CaCl,, 0.6% CHAPS. Bound protein was eluted with 0.1 M 
CH,COOH, pH 4.0, 0.5 M NaCl, 10 mM EDTA and 0.6% CHAPS. 
The eluate was neutralized with 0.1 volumes of 1.0 M Tris, pH 9.0. 
Approximately 0.5 mg protein was obtained from 0.5 kg of bovine 
mammary gland by 8 consecutive runs of the membrane xtract over 
the column. 
2.4. Ligand blotting and immunoblotting analyses 
Proteins were resolved by sodium dodecyl sulphate polyacrylamide 
gel electrophoresis (SDS-PAGE; see below) and transferred electro- 
phoretically to polyvinylidene diflouride (PVDF) filters, which were 
then incubated with approximately 30 pM of ‘251-labeled RAP. After 
washing, bound ligands were visualized by autoradiography [14]. 
The same filters were used for immunoblotting analysis, following a 
standard procedure with a primary polyclonal rabbit antibody, a sec- 
ondary peroxidase-conjugated antibody and visualization of bound 
antibody with the ECL immunoblotting detection kit. 
2.5. Cell culture, whole cell ligand binding, and degradation experiments 
The following cell lines were cultured as described previously [14,15]: 
the human breast carcinoma cell line MCF-7 (ATCC HTB 22); the 
human breast carcinoma cell line T47D (ATCC HTB 133); the bovine 
mamma epithelial cell line BMGE (a gift from Dr. W.W. Franke, 
German Cancer Research Center, Heidelberg, Germany [16]); COS-1 
african green monkey kidney cells (ATCC CRL 1651). 
For whole cell binding assays of RAP, cell monolayers were incu- 
bated with 5 uM 1”‘IlRAP with or without 100 nM non-radioactive 
RAP at 4°C for 16 h: by which time the cell associated radioactivity 
was determined [14]. 
Cellular endocytosis of RAP was estimated from the degradation by 
the cells of radiolabelled RAP into trichloroacetic acid (TCA)-soluble 
material. Briefly, serum-free cultures of confluent cells were incubated 
with around 5 pM [‘*‘I]RAP for 16 h at 4°C in order to allow the ligand 
to bind to the cells. The cells were then transferred to 37°C and at 
various time points thereafter, intact and degraded ligand in the media 
were determined as the TCA-nrecinitable and -soluble radioactivity, 
respectively [14]. 
Trypsin treatment of MCF-7 cells was performed by exposing conflu- 
ent cultures to 200 &ml trvusin in PBS at 37°C for 20 min. The trypsin 
was then inactivated-by soy bean trypsin inhibitor (5OO,@ml). Coutrol 
cultures were incubated in parallel in the same buffer without trypsin. 
Both sets of cultures were harvested by scraping and centrifugation. 
2.6. Various procedures 
SDS-PAGE and silver staining were performed by standard methods 
in 616% gradient gels. The following M, markers were used: myosin 
(M, 200,000); E. co/i/?-galactosidase (M, 116,000); phosphorylase b(A& 
97,400); bovine serum albumin (Mr 66,200); ovalbumin (A4, 43,000). 
For N-terminal amino acid sequencing, proteins were resolved by SDS- 
PAGE, electroblotted onto a ProBlott filter, and sequenced irectly 
[17]. Automated Edman degradation was carried out with an 
ABI 477A/120A pro&ein sequencer (Applied Biosystems), using stand- 
ard programs. 
3. Results 
3.1. RAP-binding proteins in cell membranes from mammary 
gland and mammary epithelial cell lines 
Fig. 1 shows ligand blotting analysis of RAP binding to 
membrane proteins from bovine mammary gland, human pri- 
mary breast tumors and lymph node metastases, and human 
and bovine mammary epithelial cell lines. The breast tumor 
samples shown in Fig. 1 were representative of a total of 
7 primary tumors, 2 lymph node metastases and 5 benign tu- 
mors analyzed. 
Most samples showed a RAP binding activity caused by the 
a,MR/LRP a-chain, as judged from comigration with the 
a-chain of purified a,MRILRP. In addition, a previously 
uncharacterized RAP binding activity migrating with an appar- 
ent M, of 105,000 was present in all samples in varying 
amounts. The binding of “‘I-RAP to this protein was, similarly 
to the binding to a,MRILRP a-chain, Ca2’ dependent and 
abolished by 100 nM non-radioactive ligand (data not shown). 
Minor bands between the two major ones may represent 
degradation products of a,MRlLRP a-chain; the weak RAP 
binding activity of LDL-R, migrating at M, 130,000 [18]; or 
other, unknown RAP-binding proteins. gp330, migrating 
slower than a,MR/LRP a-chain [19], was not observed. 
3.2. Purification and characterization of RAP-binding proteins 
from bovine mammary gland and MCF-7 cells 
The RAP-binding proteins from bovine mammary gland and 
from MCF-7 cells were purified by single step affinity chroma- 
tography with RAP immobilized on Sepharose. Analysing the 
purified fractions by RAP ligand blotting analysis, a band pat- 
tern similar to that in the cell membrane preparations was 
found (Fig. 2A). 
Fig. 1. Ligand blotting analysis of RAP binding proteins in cell mem- 
branes from mammary glands and mammary epithelial cell lines. Fifty 
ng a,MR/LRP and cell membrane samples corresponding to 5 fig 
protein from the indicated sources were resolved by SDS-PAGE in 
4-l 6% gradient gels and assayed for [“‘I]RAP binding by ligaud blot- 
ting analysis. M, markers are indicated on the left. m.g. = mammary 
gland. 
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Fig. 2. Purification and characterization of RAP-binding proteins from bovine mammary gland and MCF-7 cells. Purified a,MR/LRP, purified RAP 
binding proteins from MCF-7 cells and from bovine mammary gland were subjected to SDS-PAGE in 4-16% gradient gels. The lanes contain 50 ng 
a,MR/LRP, 65 ng RAP-binding protein from bovine mammary gland or 8 ng RAP-binding protein from MCF-7 cells. (A) Shows ligand blotting 
analysis with ‘2sI-RAP, (B) silver staining and (C) immunoblotting analysis with rabbit polyclonal anti-VLDL-R IgG or non-immune rabbit IgG. 
The lettering of the bands on the silver stained gels of purified RAP-binding proteins from bovine mammary gland (ax) refer to discussion in the 
text. M, markers are indicated on the left. m.g. = mammary gland. 
Due to the ready access to large quantities of tissue, the 
preparation of RAP binding proteins from bovine mammary 
gland was used for protein sequencing. SDS-PAGE and silver 
staining of the preparation showed 5 polypeptides (Fig. 2B). 
Bands a and d comigrated with the a- and the B-chain of 
purified a,MR/LRP, respectively. The identity of band d was 
confirmed by N-terminal amino acid sequencing, the N-termi- 
nal 9 amino acids showing a 100% identity to the p-chain of 
human a,MWLRP (data not shown). Band e migrates close to 
recombinant human RAP (not shown), and this band probably 
represents copurifying RAP. Band b (kf, 400,000) was not 
identified. 
The sequence of the N-terminal 14 amino acids of band c, 
comigrating with the A4, 105,000 RAP binding activity, is 
shown in Table 1. No PTH derivatives were detected in cycle 
9. Of the remaining 13 amino acids, 10 and 9 were identical to 
the amino acids in the corresponding positions in human and 
rabbit VLDL-R, respectively [ 10,111. Bovine VLDL-R has not 
yet been cloned. All differences between the bovine ikf, 105,000 
RAP binding protein and human and rabbit VLDL-R could be 
accounted for by single nucleotide changes. The fact that no 
PTH derivative was detected in cycle 9 was in agreement with 
expectances if the amino acid in that position is a Cys involved 
in a disulfide bridge, as in human and rabbit VLDL-R. The 
purified protein shows a much lower identity to bovine, human, 
rabbit, and hamster LDL-R. The sequence was not compatible 
Table 1 
N-terminal amino acid sequences of bovine h4, 105,000 RAP binding protein and VLDL-R and LDL-R from various species 
Protein Cycle 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Bovine 
M, 105,000 RAP 
binding protein T G A G R K A K X* E A N F 
Human VLDL-R** T*** G T G R K A K C E P S 
Rabbit VLDL-R T K T ?? R K T E c E A S 
; ; 
Bovine LDL-R K v B D N C 
z E N E Human LDL-R A G T A V D R C 
: D K C 
R ; 
Rabbit LDL-R G A A A z R R E P 
Hamster LDL-R 2 H & A A E D r C D R ” E E 
*No PTH derivative was found in step 9; see the text for a further discussion. 
**The sequences of the VLDL-Rs and LDL-Rs were obtained from the following sources: human VLDL-R cDNA [l 11; rabbit VLDL-R cDNA [lo]; 
bovine LDL-R protein [26]; human LDL-R cDNA [271; rabbit LDL-R cDNA [28]; hamster LDL-R cDNA [29]. 
***The underlined amino acids in the VLDL-Rs and LDL-Rs are those that are identical to the amino acids in the corresponding positions in bovine 





Fig. 3. Binding and degradation of RAP in MCF-7 cells. (A) Effect of 
trypsin treatment on the content of VLDL-R in MCF-7 cell mem- 
branes. Cell membrane samples corresponding to 5 pg of total protein 
from control MCF-7 cells (a) or trypsin-treated MCF-7 cells (b) were 
resolved by SDS-PAGE in 416% gradient gels and assayed for RAP 
binding by ligand blotting analysis. M, markers are indicated on the 
left. (B) Whole cell binding of ?-RAP to MCF-7 cells. 5 pM “‘I-RAP 
was incubated with MCF-‘I cell monolayers without (a) or with (b) 100 
nM non-radioactive RAP for 16 h at 4°C. The cell bound fraction 
(mean f S.D. of triple determinations) are indicated. (C) Assay of 
degradation of RAP and a,M* by MCF-7 cells. Serum-free cultures of 
confluent MCF-7 cells were incubated for 16 h at 4°C with 5 pM 
“‘I-RAP (0) or 5 pM ‘ZSI-cc,M* (0). After transfer to 37”C, the percent- 
ages of degraded ligand in the media was determined at the indicated 
time points. Means and standard eviations of triple determinations are 
shown. The experiment shown is a typical one out of a total of 6. The 
amounts degraded in the presence of 100 nM non-radioactive RAP has 
been subtracted from all values. 
with the protein being a degradation product of a,MRlLRP or 
gp330. No sequences besides those of the M, 105,000 RAP 
binding protein and a,MRILRP /?-chain was detectable in the 
J4, 100,000 region of the gel. 
Immunoblotting analysis with a polyclonal rabbit peptide 
antibody against the C-terminus of human and rabbit VLDL-R 
revealed specific immunoreactivity comigrating with the it4, 
105,000 RAP binding activity in the preparations from bovine 
mammary gland and MCF-7 cells (Fig. 2C). 
We conclude that the purified M, 105,000 RAP binding pro- 
tein from bovine mammary gland and MCF-7 cells is identical 
or closely related to VLDL-R. 
3.3. Binding and endocytosis of RAP by MCF-7 cells 
In ligand blotting analysis (see Figs. 1 and 2), all detectable 
RAP binding activity in MCF-7 cells comigrated with the 
VLDL-R immunoreactivity, even with prolonged exposures of 
autoradiographic films. We estimate from these data that 
VLDL-R constitutes more than 95% of the RAP binding activ- 
ity of MCF-7 cells, and the data are in agreement with MCF-7 
cells being devoid of a,MR/LRP, gp330 and putative RAP 
binding activity of LDL-R. a,MR/LRP was also undetect- 
able in MCF-7 cells by immunoblotting analysis with monoclo- 
nal antibodies against both the a-chain as well as the /?-chain 
(data not shown). Trypsin treatment of MCF-7 cells led to 
digestion of VLDL-R, as revealed by RAP ligand blotting anal- 
ysis (Fig. 3A). This shows that this receptor is exposed at the 
cell surface. Whole cell binding assays revealed that the cells 
were able to bind RAP at 4°C (Fig. 3B). In contrast, there was 
no measurable binding (C 3% of the RAP binding) of a,M 
rendered a,MR/LRP-binding by methyl amine treatment 
(a,M*) [20,21]. Parallel control experiments were performed 
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with the same preparations of radiolabelled RAP and a,M* 
and COS-1 cells, expressing abundant a,MR/LRP and devoid 
of other RAP binding proteins [12]. The binding of a,M* to 
COS-1 cells amounted to 55% of the RAP binding (data not 
shown). These results confirm the absence of a,MR/LRP in 
MCF-7 cells. These cells therefore seemed well suited for inves- 
tigating whether VLDL-R was able to mediate endocytosis of 
RAP. 
The ability of the cells to endocytose RAP was estimated 
from the ensuing conversion of [‘=IJRAP to TCA-soluble radio- 
activity during incubation at 37°C. MCF-7 cells were found 
to endocytose RAP quite efficiently, around 20% of the total 
amount added being degraded in 4 h. There was no measurable 
endocytosis (< 1%) of a,M* (Fig. 3C), in agreement with the 
binding results. In control experiments with COS-1 cells, the 
a,M* degradation was found to be 75% of that of RAP. We 
conclude that VLDL-R is able to mediate endocytosis of RAP. 
4. Discussion 
In the present communication, we describe an M, 105,000 
RAP binding protein from mammary gland and mammary 
epithelial cell lines, which is identical or closely related to 
VLDL-R, as judged by its N-terminal amino acid sequence and 
its reactivity with a peptide antibody against the C-terminus of 
VLDL-R. The observed M, agrees with that expected from the 
cDNAs for rabbit and human VLDL-R [lo, 111. 
VLDL-R was the fourth mammalian member of the LDL-R 
family to be identified [lO,ll], after LDL-R itself, a,MR/LRP 
and gp330 (see [2]). The extracellular ligand-binding part of the 
prototype of the family, LDL-R, contains, mentioned from the 
N-terminus, a cluster of 7 complement ype repeats, an EGF 
precursor homology domain, and a domain with O-linked sug- 
ars. VLDL-R has a similar structure, the overall amino acid 
identity between the two receptors being around 40%. How- 
ever, VLDL-R has an additional complement type repeat 
[lO,ll]. gp330 has only been partially sequenced. The ligand 
binding a,MRILRP a-chain has several clusters of complement 
type repeats and EGF precursor domains (see [2]). A large 
cluster of 8 complement ype repeats near the N-terminus of 
a2MRlLRP has been shown to be indispensable for binding of 
RAP [22,23]. Although LDL-R, with 7 complement-type re- 
peats, has been reported to possess a weak RAP-binding activ- 
ity [6], the presence of a cluster of 8 repeats like in VLDL-R, 
a,MRILRP and possibly gp330, may be a crucial feature in 
conferring high RAP binding affinity. 
In the cytoplasmic portion, LDL-R and VLDL-R have one, 
and aZMRILRP and gp330 two copies of the NPXY sequence 
needed for rapid endocytosis via clathrin-coated pits [2], in 
agreement with the functions of these receptors in endocytosis. 
One function of VLDL-R is believed to be endocytosis of apo- 
lipoprotein E-containing lipoprotein particles [lO,l 11, but the 
ligand binding specificity of VLDL-R has only been incom- 
pletely elucidated. The observation that VLDL-R resembles 
a,MRILRP and gp330 with respect to RAP binding suggest 
that the three receptors may share other ligands too. 
The physiological function of RAP is unknown. Sequence 
analysis of RAP protein and cDNA shows that it has a signal 
peptide that is cleaved post-translationally [5]. RAP has been 
demonstrated in endoplasmic reticulum, but is not found in 
blood plasma or extracellularly in RAP synthesizing cell lines 
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(see [2]). This is in agreement with the fact that RAP has a 
C-terminal endoplasmic reticulum retrieval signal (see [24]). As 
judged from pulse-chase studies, RAP interacts with a,MR/ 
LRP and gp330 before they reach the cell surface [5,25]. It 
therefore appears that its function in relation to these receptors 
may be to act as a chaperone or an intracellular modulator of 
ligand/receptor interaction. It does not appear to be a normal 
extracellular ligand for the receptors. Whatever the function 
may be, the present findings suggest hat it involves interactions 
with VLDL-R as well as with a,MR/LRP and gp330. 
The present description of VLDL-R in mammary epithelial 
cell lines does not necessarily imply its presence in breast epithe- 
lium in vivo. Immunohistochemical studies will be able to re- 
veal the relative cellular localization of VLDL-R and a,MR/ 
LRP in normal and malignant mammary tissue. In general, 
VLDL-R may function as an endocytosis receptor for a variety 
of ligands in cell types different from those expressing aIMR/ 
LRP and gp330. 
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